使用苯达莫司汀联合利妥昔单抗治疗后再用利妥昔单抗维持治疗的滤泡性淋巴瘤患者发生进行性多灶性白质脑病。 - Suppr | 超能文献

相似文献

1

Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance.使用苯达莫司汀联合利妥昔单抗治疗后再用利妥昔单抗维持治疗的滤泡性淋巴瘤患者发生进行性多灶性白质脑病。

Br J Haematol. 2020 May;189(4):e140-e144. doi: 10.1111/bjh.16563. Epub 2020 Mar 9.

2

Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.由于严重血液学和感染性毒性，苯达莫司汀、米托蒽醌和利妥昔单抗用于未经治疗的高危滤泡性淋巴瘤患者的II期研究提前终止。

Br J Haematol. 2016 Nov;175(3):531-533. doi: 10.1111/bjh.13863. Epub 2015 Dec 18.

3

Progressive multifocal leukoencephalopathy during rituximab maintenance after rituximab and bendamustine treatment for relapsed follicular lymphoma.利妥昔单抗和苯达莫司汀治疗复发滤泡性淋巴瘤后利妥昔单抗维持治疗期间发生的进行性多灶性白质脑病。

Ann Hematol. 2020 Sep;99(9):2191-2192. doi: 10.1007/s00277-020-04143-x. Epub 2020 Jun 17.

4

Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.在 GADOLIN Ⅲ期研究中，评估奥滨尤妥珠单抗在利妥昔单抗难治性滤泡淋巴瘤患者中的药代动力学、暴露量、疗效和安全性。

Br J Clin Pharmacol. 2019 Sep;85(9):1935-1945. doi: 10.1111/bcp.13974. Epub 2019 Jul 12.

5

Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study.苯达莫司汀暴露对滤泡性淋巴瘤患者接受苯达莫司汀与利妥昔单抗联合治疗后淋巴细胞减少风险的临床影响：一项单机构回顾性研究

Ann Hematol. 2022 Jan;101(1):209-211. doi: 10.1007/s00277-020-04388-6. Epub 2021 Jan 3.

6

Histiocytic Sarcoma Associated With Follicular Lymphoma: Evidence for Dramatic Response With Rituximab and Bendamustine Alone and a Review of the Literature.伴有滤泡性淋巴瘤的组织细胞肉瘤：利妥昔单抗和苯达莫司汀单独应用的显著缓解证据及文献复习。

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e1-e8. doi: 10.1016/j.clml.2018.10.004. Epub 2018 Oct 13.

7

Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.苯达莫司汀联合利妥昔单抗对比 R-CHOP 一线治疗 3A 级滤泡性淋巴瘤患者：一项多中心回顾性研究的证据。

Oncologist. 2018 Apr;23(4):454-460. doi: 10.1634/theoncologist.2017-0037. Epub 2018 Jan 9.

8

A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).一项由意大利淋巴瘤基金会（FIL）开展的 II 期研究，在老年晚期滤泡淋巴瘤患者中采用利妥昔单抗、苯达莫司汀、米托蒽醌（R-BM）短程诱导，随后进行利妥昔单抗巩固治疗。

Br J Haematol. 2021 Apr;193(2):280-289. doi: 10.1111/bjh.17283. Epub 2021 Jan 21.

9

Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas.对于惰性 B 细胞淋巴瘤有良好反应的病例，减少苯达莫司汀联合利妥昔单抗治疗周期。

Hematol Oncol. 2021 Oct;39(4):465-472. doi: 10.1002/hon.2871. Epub 2021 May 2.

10

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.在 GADOLIN 研究中，接受奥滨尤妥珠单抗联合苯达莫司汀诱导及奥滨尤妥珠单抗维持治疗的利妥昔单抗难治性惰性非霍奇金淋巴瘤患者具有总生存获益。

J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27.

引用本文的文献

1

Need for combined therapy for a rare case of autoimmune autonomic ganglionopathy: A case report.罕见自身免疫性自主神经节病联合治疗的必要性：一例报告

World J Methodol. 2025 Dec 20;15(4):101459. doi: 10.5662/wjm.v15.i4.101459.

2

JC Polyomavirus Infection: A Narrative Review.JC多瘤病毒感染：一篇叙述性综述

Infect Dis Ther. 2025 Sep;14(9):2007-2028. doi: 10.1007/s40121-025-01199-y. Epub 2025 Jul 27.

3

Progressive multifocal leukoencephalopathy during 4 years of Palbociclib for advanced breast cancer with a history of follicular lymphoma patient.